Cancer Drug Antitrust Claims

NEW YORK – The Second Circuit ruled that a Russian pharmaceutical firm’s antitrust claims were barred by the Foreign Trade Antitrust Improvements Act, because the alleged price-fixing and kickbacks aimed at thwarting the firm’s U.S. launch of cancer-treatment drugs occurred in Russia. 

%d bloggers like this: